Drug intelligence / Profile preview

OM3-MAG

Development stage
Preclinical
Lead developer
Nestlé
Modality
Small Molecules
Administration
Oral
01

Overview

OM3-MAG is a dietary supplement formulation of omega-3 long-chain polyunsaturated fatty acids (most commonly including eicosapentaenoic acid, EPA, and docosahexaenoic acid, DHA) in a monoacylglycerol (MAG) structure rather than the more conventional triacylglycerol (TAG) or ethyl ester (EE) forms. The MAG form is considered "pre-digested," allowing for enhanced bioavailability and absorption of EPA and DHA, particularly under conditions of impaired fat digestion or low dietary fat intake. Clinical trials indicate that OM3-MAG results in significantly higher plasma concentrations of EPA and DHA compared to ethyl ester or triacylglycerol forms at equivalent doses, and thus may be especially beneficial for individuals with lipid malabsorption, obesity, cystic fibrosis, or those at high cardiovascular risk needing high-dose omega-3 therapy while on a low-fat diet. The OM3-MAG monoacylglycerol form does not rely on pancreatic lipase activity for absorption, making it more suitable for populations with reduced digestive enzyme function[1][2][3].

Other names
omega-3 monoacylglycerolomega3 monoacylglycerolomega 3 monoacylglycerolOM3-sn-1(3)-monoacylglycerolmonoglyceride omega-3
02

Targets

CES2 (Carboxylesterase 2)FFAR4 (Free fatty acid receptor 4)NF-κBSREBP-1 / SREBF1 (SREBP-1)PPARG (Peroxisome proliferator-activated receptor gamma)

Beyond the preview

Go deeper on OM3-MAG.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on OM3-MAG.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call